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Case ReportMutation in the mitochondrial translation elongation factor
EFTs results in severe infantile liver failure
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Department of Genetics, Hôpital Necker-Enfants Malades, Université Paris Descartes and INSERM U781, 149 rue de Sèvres, 75015 Paris, FranceBackground & Aims:Multiple respiratory chain deﬁciencies rep- 80 different subunits, 13 of them being encoded by the mitochon-
resent a common cause of mitochondrial diseases and often
result in hepatic failure. A signiﬁcant fraction of patients present
mitochondrial DNA depletion but a number of cases remain
unexplained. The aim of our study was to identify the disease
causing gene in a kindred with intrauterine growth retardation,
neonatal lactic acidosis, liver dysfunction and multiple respira-
tory chain deﬁciency in muscle.
Methods:Homozygosity mapping was performed by 50K SNP
genotyping and candidate genes were successively analyzed by
direct sequencing on genomic DNA of the family members.
Results: SNP genotyping detected several regions of homozygos-
ity in which we focused our attention to genes involved in mito-
chondrial translation. We sequenced the TSFM gene, encoding
the mitochondrial translation factor EFTs and identiﬁed a homo-
zygous mutation changing a highly conserved arginine into a
tryptophan (R312W).
Conclusions: This mutation has been previously reported in two
unrelated kindred presenting two distinct syndromes (fatal mito-
chondrial encephalomyopathy and hypertrophic cardiomyopathy
respectively). The description of a third syndrome associated with
a same TSFM mutation gives support to the broad clinical and
genetic heterogeneity of mitochondrial translation deﬁciencies
in human. It suggests that mitochondrial translation deﬁciency
represents a growing cause of hepatic failure of mitochondrial ori-
gin in infants.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatic failure is a frequent feature in respiratory chain deﬁ-
ciency. Patients usually present with liver insufﬁciency, cholesta-
sis, cirrhosis and/or cytolysis soon after birth or during the ﬁrst
weeks of life. Respiratory chain (RC) enzyme deﬁciency can be
diagnosed on needle biopsy of the liver. The mitochondrial respi-
ratory chain consists of ﬁve complexes composed of more thanJournal of Hepatology 20
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except complex II, contain both nuclearly and mitochondrially
encoded proteins. Mitochondrial genes are translated within
the mitochondria by a speciﬁc translation apparatus comprising
2 ribosomal and 22 transfer RNAs (rRNA and tRNA) encoded by
the mtDNA and hundreds of proteins (ribosomal proteins,
amino-acyl tRNA synthetases, initiation, elongation, and termina-
tion factors) encoded by nuclear genes. Multiple RC enzyme deﬁ-
ciency with a severe decrease of liver mtDNA copy number
(mtDNA depletion) has been found in a signiﬁcant fraction of
patients and ascribed to mutations in genes involved in mtDNA
replication or dNTP supply for mtDNA replication (POLG1 [1],
PEO1 [2], DGUOK [3], and MPV17 [4]). Few cases of severe hepatic
failure have been ascribed to genes in the mitochondrial transla-
tion machinery, namely TRMU [5], a mitochondrial tRNA-modify-
ing enzyme and GFM1 [6,7], a translation elongation factor. Yet a
number of cases of liver failure and RC deﬁciency remain unex-
plained. Here, we show that the TSFM gene encoding EFTs, the
mitochondrial translation elongation factor S, is a cause of severe
liver failure. This supports the view that mitochondrial transla-
tion deﬁciency represents an increasing cause of early onset
hepatic failure.Patients and methods
Patient 1 (V-4), a girl, was the fourth child of consanguineous parents from Mali
(Fig. 1). She presented intrauterine growth retardation and died at day 1 for
unknown reasons. Patient 2 (V-6) was the sixth child of the sibship. She had intra-
uterine growth retardation and was born at 37 weeks of pregnancy. Birth weight
was 2330 g, length 46 cm and head circumference 32 cm. Neurological examina-
tion was normal at birth but she refused feeding and was found to have persistent
hyperlactatemia (lactate: 20 mmol/L, control values <2.2 mmol/L), anemia, and
jaundice (total bilirubin: 17 lmol/L, control values <60 lmol/L). At 24 h of life,
she developed slight trunk hypotonia and cytolysis (AST: 141 UI/L, control values:
10–40). Her condition worsened at 6 weeks of age. She had major trunk hypoto-
nia, tubulopathy, and liver insufﬁciency. She died at 2 months of age. Patient 3 (V-
7), the younger sister of the sibship was born at 39 weeks of pregnancy (birth
weight 2350 g, length 47 cm, head circumference 34 cm). She had major trunk
hypotonia, hypertrophic cardiomyopathy, poor spontaneous movements, and
no sucking at birth. At day 2, she had persistent hyperlactatemia (lactate
4.4 mmol/L), cytolysis and cholestasis (AST: 47 UI/L, control values: 5–30; cGT:
36 UI/L, control values: 5–20; bilirubin 161 lmol/L, control values <60 lmol/L).
Her neurological condition worsened from day 10, she had dystonic movements,
generalized hypotonia, and she died at 2 weeks of age. Finally, the ﬁrst girl of the
sibship (V-1) was found to have an unrelated condition, minicore myopathy with
normal RC enzyme in muscle.12 vol. 56 j 294–297
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Fig. 1. Pedigree of the family. Black circles indicate patients with liver failure
and RC deﬁciency. The ﬁrst child has minicore myopathy and normal RC.
Asterisks indicate individuals that have been SNP genotyped.
Table 2. Respiratory chain activities in muscle mitochondria and ﬁbroblasts.
Muscle Fibroblasts
homogenate mitochondria
P2 C P3 C P3 C
Absolute activities (nmol/min/mg prot)
CI 3 8-32 10 47-182
CII 16 18-70 110 69-268 14 11-42
CIII 64 67-268 587 421-1654 112 50-187
CIV 16 86-342 235 607-2419 84 50-197
CV 242 220-862
CI+III 41 138-549
CII+III 18 17-63 206 171-679 39 18-68
CS 59 54-210 107 54-210 94 37-143
Activity ratios
CIV/CI 5.7 10.6 ± 0.8 23.5 10.9 ± 2.0
CIV/CII 1.0 5.4 ± 0.4 2.1 7.8 ± 0.7 6.0 4.8 ± 0.4
CIV/CIII 0.2 1.3 ± 0.1 0.4 1.2 ± 0.1 0.8 1.0 ± 0.1
CIV/CV 1.0 2.6 ± 0.2
CIV/CI+III 5.7 3.7 ± 0.5
CIV/CII+III 0.9 5.4 ± 0.6 1.1 3.3 ± 0.4 2.1 2.9 ± 0.2
CI–CV, complexes I–V; CS, citrate synthase; LM, lauryl-maltoside; P1–P4, patients
1–4; C, control; abnormal values are in bold.
JOURNAL OF HEPATOLOGYRespiratory chain analysis, protein analysis, antibodies and ECL detection
Spectrophotometric assays of respiratory chain enzymes were carried out as
previously described [8]. For blue native–polyacrylamide gel electrophoresis
(BN–PAGE), mitochondria and OXPHOS complexes were isolated as described
[9]. Solubilized OXPHOS proteins (15 lg) were loaded on a 4–16% acrylamide
non-denaturing gradient gel (Invitrogen). Immunodetection was performed
using the following primary antibodies: anti-CI-Grim19, CII-SDHA, CIII-core2,
CIV-COX1 and CV-subunit b (mouse monoclonal antibodies, Mitosciences).
Secondary antibody detection was performed using peroxidase-conjugated
anti-mouse IgGs (Abcam). The signal was generated using ECL (Pierce, Rockford,
USA).Homozygosity mapping and mutation screening
We performed SNP genotyping using the GeneChip Human Mapping 50K Array
Xba 142 2.0 for individuals designed with an asterisk (Fig. 1). The exons of the
TSFM gene were ampliﬁed using speciﬁc primers (Table 1) after an initial denatur-
ation at 94 C for 5 min, followed by 30 cycles of 94 C for 30 s, 55 C for 30 s, and
72 C for 30 s, and a last extension at 72 C for 10 min. Ampliﬁcation products
were puriﬁed by ExoSapIT (Amersham, Buckinghamshire, United Kingdom) and
directly sequenced using the PRISM Ready Reaction Sequencing Kit (Perkin-
Elmer, Oak Brook, IL) on an automatic sequencer (ABI 3130xl; PE Applied Biosys-
tems, Foster City, CA).Results
Respiratory chain enzyme and mtDNA analysis
Patients 2 and 3 presented reduced absolute activities of com-
plexes I and IV in muscles as well as abnormal activity ratios. Cul-
tured skin ﬁbroblasts of patient 3 showed normal RC enzyme
activities (Table 2). Large scale mtDNA deletion, mtDNA depletion
and common point mutations (m.3243A>G, m.8344A>G,
m.8993T>G) were excluded by using appropriate techniques in








Journal of Hepatology 201BN–PAGE analysis
BN–PAGE analysis of mitoplasts isolated from skin ﬁbroblasts of
patient 3 revealed a marked decrease of fully-assembled com-
plexes I and IV as compared to controls whereas complex II
was normal (Fig. 2). Moreover, lower molecular weight subcom-
plexes were observed following incubation with anti-GRIM-19,
and anti-ATPase b antibodies. This result was consistent with a
combined RC deﬁciency affecting mtDNA encoded complexes
and possibly a translation deﬁciency.
Homozygosity mapping and TSFM sequencing
SNP genotyping using 50K Xba array allowed to identify one
region of homozygosity of 40 Mb on chromosome 12
(chr12:29,624,783-69,537,647). This region encompassed more
than 440 genes, 19 of them encoding either mitochondrial pro-
teins or proteins predicted to be targeted to the mitochondria.
Moreover, two large regions of 12 and 30 Mb on chromosomes
14 (chr14:80,074,862-92,786,599) and 19 (chr19:9,660,405-
49,024,587) could not be excluded. As the abnormal BN–PAGE
proﬁle observed in patient 3 was suggestive of mitochondrial




















Fig. 2. BN–PAGE analysis of mitochondria from cultured skin ﬁbroblasts of
patient 3 (P3) and control (C) using antibodies against GRIM19 for complex I
(CI), SDHA for complex II (CII), core 2 for complex III (CIII), COX2 for complex
IV (CIV), and F1b subunit for complex V (CV). Filled arrows indicate low amount
of CI, CIV, and CV. Empty arrows indicate additional bands.
Case Reportproteins of the mitochondrial translation machinery namely
YARS2 and TSFM on chromosome 12, MRPL4, MRPL34, MRPS12,
GTPBP3 and SARS2 on chromosome 19. After having excluded
mutations in the coding sequences and exon–intron boundaries
of YARS2, MRPL4, MRPL34, GTPBP3 and SARS2, we identiﬁed a
homozygous C to T transversion at nucleotide 934 in exon 6 of
the TSFM gene in patients 3–4. This mutations changed a highly
conserved arginine into a tryptophan (R312W, relative to Gen-
bank accession number NM_005726, corresponding to R333W
previously reported). The two parents, individual V-1 and the
healthy sister (V-3) were heterozygous for this mutation.Discussion
Here, we report on a homozygous TSFM mutation in a case of
neonatal onset hepatic failure and multiple RC deﬁciency. This
TSFM mutation was identiﬁed in a consanguineous family by
combining SNP genotyping and candidate gene approach based
on an abnormal BN–PAGE proﬁle. The deleterious nature of the
R312W mutation has been previously established by expression
studies in patient’s ﬁbroblasts demonstrating that the mutation
is indeed the cause of the disease and results in an abnormal
translation of mitochondrially-encoded proteins [10].
TSFM mutations have been rarely reported and therefore rep-
resent a rare cause of mitochondrial disorders. Previously
reported patients had fatal mitochondrial encephalomyopathy,
hypertrophic cardiomyopathy [10] or both [11]. Hitherto how-
ever, TSFMmutations had never been reported as a cause of hepa-
tic failure in human. The clinical heterogeneity of TSFMmutations
is particularly intriguing as all patients presented exactly the
same mutation. Intrafamilial heterogeneity also occurs here as
patient 3, but not patient 2, had hypertrophic cardiomyopathy
at day 2. Unknown factors possibly related to speciﬁc polymor-
phisms in other translation factors, genetic background, adaptive
mechanisms and/or susceptibility to external factors should con-
tribute to this clinical heterogeneity.296 Journal of Hepatology 201Liver failure is a common feature in multiple RC deﬁciencies.
Some patients present severe liver mtDNA depletion related to
DGUOK [3] POLG1 [1], PEO1 [2] or MPV17 [4] mutations. Others
had translation deﬁciency caused by TRMU and GFM1 mutations
[5–7]. The observation of TSFM mutations in two patients with
liver failure suggests that TSFM should now be regarded as a dis-
ease gene in hepatic failure. Mitochondrial translation deﬁciency
represents therefore a cause of hepatic failure in neonates. Yet it
should be borne in mind that a mutation in genes of the transla-
tion machinery was a rare cause of liver failure in our series as 3/
74 patients with liver dysfunction were found to carry GFM1 (one
patient) and TRMU mutations (two patients).
The family reported in this study is part of a cohort of 101
patients with isolated hepatic failure and combined RC deﬁ-
ciency. Among them, 26.7% present severe mtDNA depletion
related to mutations in DGUOK, POLG1, MPV17 or PEO1. Whether
the remaining 70 patients with normal mtDNA content and no
TRMU, GFM1 and TSFM mutations present translation deﬁciency
has still to be determined. Nevertheless, the systematic study of
mtDNA allowed to exclude mtDNA mutations in all patients.
Therefore, this emphasizes that nuclear gene mutations underlie
these mitochondrial hepatic failures.
In conclusion, while mtDNA depletion has long been
regarded as a frequent cause of hepatocellular insufﬁciency or
liver failure (DGUOK [3], POLG1 [1], MPV17 [4] and PEO1 [2]
mutations), we suggest to consider abnormal mitochondrial
translation as a novel cause of liver failure in the respiratory
chain deﬁciency.Conﬂict of interest
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